Actively Recruiting
Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients: a Triple Blinded, Randomized Controlled Trial to Assess the Efficacy of Tranexamic Acid for Hemostasis
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-02-10
150
Participants Needed
1
Research Sites
30 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the use of tranexamic acid to reduce bleeding during and after surgery for metastatic spinal tumors in patients with lung cancer. This clinical trial aims to compare bleeding amounts between patients receiving tranexamic acid and those who do not, addressing the risk of severe complications caused by massive blood loss during tumor removal. The study is conducted as a triple-blinded, randomized controlled trial to assess the effectiveness of tranexamic acid for controlling bleeding. Participants are randomly assigned to one of two groups. One group receives an intravenous drip of tranexamic acid before the incision, tranexamic acid-soaked gauze applied to the wound before closure, and intravenous tranexamic acid three times within 24 hours after surgery. The other group receives a similar procedure using a saline solution as a placebo. Treatments are given around the time of surgery to compare their effects on blood loss. During the study, researchers measure total blood loss over three days after surgery and intraoperative blood loss once after surgery. They also track the volume of blood transfusions given during surgery. Participant health and bleeding outcomes are closely monitored to evaluate the treatment's impact. The study runs from December 2023 to August 2026 and includes patients aged 10 to 80 years who undergo specific spinal tumor surgery.
CONDITIONS
Brief Title
Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed as metastatic carcinoma of the thoracolumbar spine
- Solitary neoplasm involving only one segment of spine
- Patients undergoing separation surgery
You will not qualify if you...
- Abnormal coagulation function before surgery
- Allergy to tranexamic acid
- Neoplasm involving more than one segment of spine
- Patients with rich blood supply who need embolization
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 24 hours during and after surgery
Participants receive tranexamic acid or placebo during and shortly after surgery to prevent bleeding.
1 surgery day and administration of medication over 24 hours post-surgery
Duration - 3 days postoperatively
Participants are monitored for blood loss and other outcomes after surgery.
1 visit 3 days after surgery
Trial Site Locations
Total: 1 location
1
the Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 311200
Actively Recruiting
Research Team
H
Hengyuan Li, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here